Novel Examples of Non-ATP Site Inhibitors
Doriano Fabbro, Ph.D., Executive Director, Expertise Kinase Platforrm, CPC, Novartis Pharma AG
Comprehensive Assay of Kinase Catalytic Activity Reveals Features of Kinase Inhibitor Selectivity and Novel Kinase-Inhibitor Interactions
Jeffrey R. Petersen, Ph.D., Associate Professor, Cancer Genetics and Signaling, Fox Chase Cancer Center
Activation-State Dependent Conformational Differences in Protein Kinases and the Role of Hydrophobic Motifs in Inactive Kinases: Lessons Learned in Drug Discovery and Optimization
Mark Ashwell, Ph.D., Vice President, Chemistry, ArQule
Development of a Mono-Selective CDK7 Inhibitor Lead
Jan Eickhoff, Ph.D., Head of Assay Development and Screening, Lead Discovery, Centrum GmBH
Targeting the Unfolded Protein Response: Discovery and Characterization of Selective First-in-Class PERK Inhibitors
Jeffrey M. Axten, Ph.D., Director, Medicinal Chemistry, Protein Dynamics DPU, Oncology Business Unit, GlaxoSmithKline
Multiple Strategies for Overcoming Kinase Inhibitor Resistance
Nathanael S. Gray, Ph.D., Assistant Professor, Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School
Pathway-Based Identification of Biomarkers for Targeted Kinase Therapeutics
An Chi, Ph.D., Research Fellow, Molecular Biomarkers Department, Merck Research Laboratory
Aptamers: A New Class of Tyrosine Kinase Inhibitors
Said Ismail, Ph.D., Associate Professor, Molecular Biology, Department of Biochemistry, Medical School, University of Jordan
Development and Activity of Inhibitors of the Atypical Mitotic Kinase Haspin
Jonathan Higgins, Ph.D., Assistant Professor, Medicine, Brigham & Women’s Hospital, Harvard Medical School
Kinase Virtual Screening with Accuracy Comparable to Experiment
Eric Martin, Ph.D., Director, Computational Chemistry, Global Discovery Chemistry, Novartis institutes for BioMedical Research
Structure-Guided Design of Biologically Active and Highly Selective Inhibitors of the CK1 Family of Protein Kinases for the Treatment of Cancer, Inflammation and Neurological Disorders
Jeffrey F. Ohren, Ph.D., CSO, Emil's Molecular Design, LLC; Senior Research Specialist, Department of Radiation Oncology, University of Michigan Medical School, Ann Arbor
Talk Title to be Announced
Milton H. Werner, Ph.D., President & CEO, Inhibikase Therapeutics, Inc.
Resistance of Akt Kinases to Dephosphorylation through ATP-Dependent Conformational Plasticity
Roger S. Armen, Ph.D., Assistant Professor of Medicinal Chemistry, Department of Pharmaceutical Sciences, Thomas Jefferson University, School of Pharmacy
Integrate Structural, Biophysical and Computational Methods to Understand Glucokinase Function and Design Novel Allosteric Activators
Xiayang Qiu, Ph.D., Senior Director, Head of Structure Biology & Biophysics, Pfizer, Inc.
Identification of DYG-out Inhibitors of LRRK2 Based on Structural Modeling and Enzyme Kinetic Studies
Min Liu, Ph.D., Assistant Director, The Laboratory of Drug Discovery for Neurodegeneration, LDDN, Harvard NeuroDiscovery Center, HNDC, Brigham and Women’s Hospital
Determining the Crystal Structures of Allosteric Kinase Inhibitor Complexes
Barbara Brandhuber, Ph.D., Director, Early Drug Discovery, Biology, Array BioPharma
Inhibiting PI3K for Treating Inflammatory Diseases
Stephen J. Shuttleworth, Ph.D., CSO, Karus Therapeutics, Ltd.
Developing Novel Drak2 Inhibitors for the Treatment of Autoimmune Diseases
Jiangping Wu, Ph.D., Professor of Medicine, Medicine, University of Montreal
Druggability and Ligandability: Structural Genomics Insights Suggest in Excess Of 10,000 Potentially Druggable Proteins in the Human Proteome
Florian Nigsch, Ph.D., Presidential Postdoctoral Fellow, Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research
Integrate Structural, Biophysical and Computational Methods to Understand Glucokinase Function and Design Novel Allosteric Activators
Xiayang Qiu, Ph.D., Senior Director, Head of Structure Biology & Biophysics, Pfizer, Inc.
Discovery of Potent, Selective, and Orally Bioavailable SIK2 Kinase Inhibitors for Multiple Disease Indications
Hariprasad Vankayalapati, Ph.D., Scientific Advisor, Arrien Pharmaceuticals
Identification of Novel Non ATP – Competitive Inhibitors against Human MAP Kinase Kinase1 (MEK1) and MEK2
Rambabu Gundla, Ph.D., Principal Scientist, Informatics, GVKBIO Sciences Pvt Ltd.